CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx completed its acquisition of Naveris, adding NavDx, the only Medicare-covered MRD test for HPV-positive head and neck and anal cancers. The transaction expands CareDx’s estimated addressable market to more than $12 billion; Naveris generated approximately $35 million in 2025 revenue, doubling year-over-year.
Key figures
- Addressable market
- $12 billion
- Naveris 2025 revenue
- $35 million
- Naveris tests commercial
- 130,000
- Medicare reimbursement rate
- $1,800
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.